Peter E. Hall

Peter E. Hall

Auto-generated profile, based on publicly available information

Peter E. Hall

Barts Cancer Institute, Queen Mary University of London, London, UK

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2009 in PLOS Biology
Verified
Journal Article
Open access
PDF file
KLKarine Loulier
Karine Loulier
JLJustin D. Lathia
Justin D. Lathia
Veronique MarthiensVeronique Marthiens
Veronique Marthiens
JRJenne Relucio
Jenne Relucio
MMMohamed R. Mughal
Mohamed R. Mughal
CFCharles Ffrench-Constant
Charles Ffrench-Constant
During embryogenesis, the neural stem cells (NSC) of the developing cerebral cortex are located in the ventricular zone (VZ) lining the cerebral ventricles. They exhibit apical and basal processes that contact the ventricular surface and the pial basement membrane, respectively. This unique architecture is important for VZ physical integrity and fate determination of NSC daughter cells. In addition, the shorter apical process is critical for interkinetic nuclear migration (INM), which enables VZ cell mitoses at the ventricular surface. Despite their importance, the mechanisms required for NSC adhesion to the ventricle are poorly understood. We have shown previously that one class of candidate adhesion molecules, laminins, are present in the ventricular region and that their integrin receptors are expressed by NSC. However, prior studies only demonstrate a role for their interaction in the attachment of the basal process to the overlying pial basement membrane. Here we use antibody-blocking and genetic experiments to reveal an additional and novel requirement for laminin/integrin interactions in apical process adhesion and NSC regulation. Transient abrogation of integrin binding and signalling using blocking antibodies to specifically target the ventricular region in utero results in abnormal INM and alterations in the orientation of NSC divisions. We found that these defects were also observed in laminin α2 deficient mice. More detailed analyses using a multidisciplinary approach to analyse stem cell behaviour by expression of fluorescent transgenes and multiphoton time-lapse imaging revealed that the transient embryonic disruption of laminin/integrin signalling at the VZ surface resulted in apical process detachment from the ventricular surface, dystrophic radial glia fibers, and substantial layering defects in the postnatal neocortex. Collectively, these data reveal novel roles for the laminin/integrin interaction in anchoring embryonic NSCs to the ventricular surface and maintaining the physical integrity of the neocortical niche, with even transient perturbations resulting in long-lasting cortical defects. The developing cerebral cortex contains bipolar neural stem cells that span the cortical layers between the inner ventricular surface and the outer pial surface of the embryonic brain. The nuclei of these cells remain near the ventricular cavity, a microenvironment or niche thought to provide vital signals. It is not known how this inner end of the bipolar stem cell is held in place, or what would happen if its attachment to the inner surface were lost. Genetic manipulation can be used to disrupt candidate molecules involved in this adhesion, but this will affect all adhesion points and complicate the results. We have therefore developed an approach to target the stem cell attachments specifically at the ventricular surface by placing blocking antibodies directly into the ventricles of mouse embryos and then expressing fluorescent markers in the stem cells to see the effects of losing this attachment in living tissue. We examined laminins and integrins, whose expression and properties make them excellent candidates. Blocking integrin signalling by antibody application caused the inner end of the stem cells to rapidly detach and then undergo aberrant cell division. We also showed that a transient block of integrins (for <2 hours) resulted in permanent malformations of the cortical layers and disrupted neuronal migration.

22 June 2012 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
JLJustin Lathia
Justin Lathia
MLMeizhang Li
Meizhang Li
PHPeter E. Hall
Peter E. Hall
JGJoseph Gallagher
Joseph Gallagher
JHJames S. Hale
James S. Hale
JRJeremy N. Rich
Jeremy N. Rich

1 September 2006 in Stem Cells
Verified
Journal Article
Open access
PDF file
PHPeter E. Hall
Peter E. Hall
JLJustin D. Lathia
Justin D. Lathia
NMNigel G. A. Miller
Nigel G. A. Miller
MCMaeve Caldwell
Maeve Caldwell
CFCharles Ffrench‐Constant
Charles Ffrench‐Constant
STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. STEM CELLS is read and written by clinical and basic scientists whose expertise encompasses the rapidly expanding fields of stem and progenitor cell biology. STEM CELLS welcomes original articles and concise reviews describing basic laboratory investigations of stem cells and the translation of their clinical aspects of characterization and manipulation from the bench to patient care. The journal covers all aspects of stem cells embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; stem cell technology: epigenetics, genomics, proteomics, and metabonomics; cancer stem cells; translational and clinical research; and regenerative medicine.

23 July 2008 in BMC Neuroscience
Verified
Journal Article
Open access
PDF file
PHPeter E Hall
Peter E Hall
JLJustin D Lathia
Justin D Lathia
MCMaeve Caldwell
Maeve Caldwell
CFCharles Ffrench-Constant
Charles Ffrench-Constant
Background: Human neural stem cells (hNSC) have the potential to provide novel cell-based therapies for neurodegenerative conditions such as multiple sclerosis and Parkinson's disease. In order to realise this goal, protocols need to be developed that allow for large quantities of hNSC to be cultured efficiently. As such, it is important to identify factors which enhance the growth of hNSC. In vivo, stem cells reside in distinct microenvironments or niches that are responsible for the maintenance of stem cell populations. A common feature of niches is the presence of the extracellular matrix molecule, laminin. Therefore, this study investigated the effect of exogenous laminin on hNSC growth. Results: To measure hNSC growth, we established culture conditions using B27-supplemented medium that enable neurospheres to grow from human neural cells plated at clonal densities. Limiting dilution assays confirmed that neurospheres were derived from single cells at these densities. Laminin was found to increase hNSC numbers as measured by this neurosphere formation. The effect of laminin was to augment the proliferation/survival of the hNSC, rather than promoting the undifferentiated state. In agreement, apoptosis was reduced in dissociated neurospheres by laminin in an integrin β1-dependent manner. Conclusion: The addition of laminin to the culture medium enhances the growth of hNSC, and may therefore aid their large-scale production.

1 January 2017 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
PCPui Ying Chan
Pui Ying Chan
PHPeter Hall
Peter Hall
GHGordon Hay
Gordon Hay
VCVictoria Cohen
Victoria Cohen
PSPeter Szlosarek
Peter Szlosarek

22 January 2016 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
TPThomas Powles
Thomas Powles
JBJ. Brown
J. Brown
JLJ. Larkin
J. Larkin
RJR. Jones
R. Jones
CRC. Ralph
C. Ralph
PNP. Nathan
P. Nathan
Preclinical work suggests SRC proteins have a role in the development of resistance to vascular endothelial growth factor (VEGF) targeted therapy in metastatic clear-cell renal cancer (mRCC). This hypothesis was tested in this trial using the SRC inhibitor saracatinib and the VEGF inhibitor cediranib. Patients with disease progression after ≥1 VEGF-targeted therapy were eligible to participate in this double-blind, randomized (1:1) phase II study. The study compared the combination cediranib 30 mg once daily (o.d.) and saracatinib 175 mg o.d. (CS) (n = 69) or cediranib 45 mg o.d. and placebo o.d. (C) (n = 69). Archived tissue was used for biomarker analysis [SRC, focal adhesion kinase (FAK), von Hippel–Lindau, protein tyrosine phosphatase 1b and hypoxia-inducible factor 2α : n = 86]. The primary end point was progression-free survival (PFS) by RECIST v1.1. Between 2010 and 2012, 138 patients were randomized across 16 UK sites. The characteristics of the two groups were well balanced. Partial responses were seen in 13.0% for C and 14.5% for CS (P > 0.05). There was no significant difference in PFS [5.4 months (3.6–7.3 months) for C and 3.9 (2.4–5.3 months) for CS; hazard ratio (HR) 1.18 (0.94–1.48)] or overall survival (OS) [14.2 months (11.2–16.8 months) for C and 10.0 (6.7–13.2 months) for CS; HR 1.28 (1.00–1.63)]. There was no significant difference in the frequency of key adverse events, dose reductions or drug discontinuations. None of the biomarkers were prognostic for PFS or OS. FAK overexpression correlated with an OS benefit [HR 2.29 (1.09–4.82), P > 0.05], but not PFS, for CS. Saracatinib did not increase the efficacy of a VEGF-targeted therapy (cediranib) in this setting. Biomarker analysis did not identify consistent predictive biomarkers. NCT00942877.